Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 18,156
Companies: 1,062
Drugs tracked: 3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

GCAR1

ICT-121 DC vaccine

Intraperitoneal infusion of FAST CEA-targeted CAR-T

Invivo CAR-T

MC-1-50

MC-1-50

MC-1-50

NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）

OKN4395

PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

PBCAR19B

PBCAR269A

PBGENE-HBV

PIC1 Injection

PRAX-628

PTOC1

RUC-4 Compound

TAEST16001

TAEST16001 cells

Targeted CEA CAR-T

[11C]CPPC Injection

anti-BCMA/CD70-CAR-T cells

anti-CD19 CAR NK

anti-CD19-CAR-T cells

Frequently asked questions